Eleven years after its founding, Boston BioLife is expanding its mission to bridge emerging science and clinical medicine by co-presenting the Translational Longevity Summit. The five-day event, scheduled for October 7-11, 2026, at Harvard's Enterprise Research Campus in Boston, will be presented by Boston BioLife and the Healthspan Action Coalition as part of Boston Longevity Week. The summit's significance lies in its ambition to convene leaders from science, medicine, technology, patient advocacy, policy, and investment to tackle one of longevity medicine's most pressing challenges: how to responsibly evaluate, translate, and advance promising discoveries into meaningful clinical applications.
For founder Joseph P. Krieger, the summit represents a pivotal milestone for the organization he started in July 2015. "When I founded Boston BioLife, the goal was to help physicians understand emerging science and determine how it could responsibly contribute to better patient care," Krieger said. "Eleven years later, this summit gives us the opportunity to expand that conversation across the entire translational ecosystem-from researchers and clinicians to patients, policymakers and investors." This expansion is critical because the gap between laboratory breakthroughs and real-world treatments remains a persistent bottleneck in longevity medicine.
Krieger's path to Boston BioLife began with an education in biochemistry and a career in medical-device technology and physician training. While creating educational programs around radiofrequency ablation and other medical technologies, he recognized that successful clinical adoption required more than introducing a new device or discovery. Healthcare professionals needed to understand the underlying science, appropriate applications, limitations, regulatory considerations, and patient-safety implications. That realization became the foundation of Boston BioLife. In a 2016 BioInformant interview, Krieger described the organization's purpose as facilitating the understanding of life-science technologies in clinical medicine and helping move innovation from "bench to bedside." He emphasized the importance of accurate research, regulatory awareness, and patient safety-principles that continue to inform Boston BioLife's educational mission today.
The Translational Longevity Summit extends that work into the rapidly evolving field of longevity. Discussions will explore aging, healthspan, regenerative medicine, personalized care, and the scientific and practical challenges involved in moving new discoveries from research environments into responsible real-world use. The summit will also emphasize cross-sector collaboration. Researchers, physicians, industry leaders, technology developers, patient advocates, policy voices, and investors each play a role in determining how emerging science is studied, funded, regulated, understood, and ultimately made accessible.
Patient participation will be an important part of that conversation. People living with illness and age-related conditions bring essential perspectives on urgency, daily function, treatment burden, and unmet needs. Their involvement can help ensure that research, education, and innovation remain connected to the people medical progress is intended to serve. "Translation does not happen within a single laboratory, company or medical practice," Krieger added. "It requires researchers, clinicians, patients, regulators, advocates and responsible industry partners to ask better questions together. That is the community we are bringing together in Boston."
For a Massachusetts native who built his career near Boston's medical, academic, and scientific institutions, holding the summit at Harvard's Enterprise Research Campus carries particular significance. The location brings Boston BioLife's original educational mission into an environment created to encourage research, innovation, and collaboration. Event information and registration are available through the Boston Longevity Week schedule, where the summit is a featured program. Eleven years after its founding, Boston BioLife's purpose remains consistent: to help the healthcare community understand emerging science and evaluate its potential relevance to patient care. In October, that enduring mission will bring a broader community together in Boston to address one of longevity medicine's most important challenges: translating scientific promise into responsible, measurable progress.
